凯赛生物
(688065)
| 流通市值：219.76亿 | | | 总市值：271.71亿 |
| 流通股本：5.83亿 | | | 总股本：7.21亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 2,837,905,343.41 | 1,900,180,844.78 | 874,529,796.39 | 3,295,051,930.28 |
| 营业总成本 | 2,280,880,449.35 | 1,508,819,010.42 | 715,775,081.82 | 2,575,128,035.09 |
| 其他经营收益 | | | | |
| 营业利润 | 578,994,704.39 | 400,869,136.59 | 192,442,645.42 | 633,753,128.53 |
| 利润总额 | 604,747,715.94 | 426,995,105.29 | 192,058,529.59 | 630,164,828.94 |
| 净利润 | 523,689,157.05 | 369,665,020.65 | 164,373,725.34 | 529,502,308.11 |
| 每股收益 | | | | |
| 其他综合收益 | -1,293,488.83 | -149,243.52 | 159,103.82 | 4,771,479.52 |
| 综合收益总额 | 522,395,668.22 | 369,515,777.13 | 164,532,829.16 | 534,273,787.63 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 11,779,048,767.7 | 11,963,391,225.63 | 12,266,514,393.47 | 11,731,393,445.38 |
| 非流动资产: | | | | |
| 非流动资产合计 | 12,833,959,459.48 | 12,649,018,006.8 | 12,290,688,331.93 | 12,150,889,527.68 |
| 资产总计 | 24,613,008,227.18 | 24,612,409,232.43 | 24,557,202,725.4 | 23,882,282,973.06 |
| 流动负债: | | | | |
| 流动负债合计 | 2,062,657,599.5 | 2,279,366,593.38 | 2,401,678,420.94 | 2,006,499,070.14 |
| 非流动负债: | | | | |
| 非流动负债合计 | 803,168,672.16 | 744,840,793 | 670,276,453.3 | 560,939,979.53 |
| 负债合计 | 2,865,826,271.66 | 3,024,207,386.38 | 3,071,954,874.24 | 2,567,439,049.67 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 17,920,276,076.51 | 17,761,223,070.68 | 17,871,373,306.46 | 17,699,754,365.74 |
| 股东权益合计 | 21,747,181,955.52 | 21,588,201,846.05 | 21,485,247,851.16 | 21,314,843,923.39 |
| 负债和股东权益合计 | 24,613,008,227.18 | 24,612,409,232.43 | 24,557,202,725.4 | 23,882,282,973.06 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 3,152,783,759.32 | 2,220,428,746.62 | 676,365,167.4 | 3,638,405,522.55 |
| 经营活动现金流出小计 | 2,536,175,583.59 | 1,469,829,513.81 | 697,359,781.31 | 3,234,282,424.87 |
| 经营活动产生的现金流量净额 | 616,608,175.73 | 750,599,232.82 | -20,994,613.91 | 404,123,097.68 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,057,556,142.19 | 356,214,739.72 | 5,712,000 | 3,552,378,756.17 |
| 投资活动现金流出小计 | 2,170,426,959.44 | 1,036,767,174.98 | 391,973,342.39 | 4,278,261,289.61 |
| 投资活动产生的现金流量净额 | -1,112,870,817.25 | -680,552,435.26 | -386,261,342.39 | -725,882,533.44 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 915,216,593.58 | 722,313,187.49 | 635,537,745.09 | 6,754,988,461.13 |
| 筹资活动现金流出小计 | 861,781,963.76 | 527,457,238.89 | 13,484,968.76 | 2,439,799,138.73 |
| 筹资活动产生的现金流量净额 | 53,434,629.82 | 194,855,948.6 | 622,052,776.33 | 4,315,189,322.4 |
| 汇率变动对现金及现金等价物的影响 | -142,559,665.98 | -117,899,096.93 | -58,707,879.13 | -58,919,577.52 |
| 现金及现金等价物净增加额 | -585,387,677.68 | 147,003,649.23 | 156,088,940.9 | 3,934,510,309.12 |
| 期末现金及现金等价物余额 | 8,535,087,344.56 | 9,267,478,671.47 | 9,276,563,963.14 | 9,120,475,022.24 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 147,003,649.23 | - | 3,934,510,309.12 |
最新报告期：2026-11-02| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华泰证券 | 张雄,庄汀洲,杨文韬 | 0.99 | 1.13 | 1.33 | 2026-11-02 |
| 申万宏源 | 周超,宋涛 | 0.98 | 1.15 | 1.40 | 2026-08-23 |
| 华泰证券 | 张雄,庄汀洲,杨文韬 | 1.18 | 1.31 | 1.41 | 2026-08-20 |